Background: Heart failure with preserved ejection fraction (HFpEF) makes up half
of diagnosed heart failure (HF) cases and has similar outcomes compared to heart failure with
reduced ejection fraction (HFrEF) but a discrepancy in knowledge and approach to treatment.
HFpEF is diagnosed using the following criteria: symptoms, preserved ejection fraction
(greater than 50%), and evidence of abnormal left ventricular filling or relaxation, or diastolic
distensibility or stiffness. Studies conducted to examine the efficacy of angiotensin receptor
blockers (ARB) (irbesartan and candesartan), thiazide diuretics (chlorthalidone), and
angiotensin converting enzyme inhibitors (ACEI) (perindopril) in the treatment of HFpEF,
showed moderate efficacy but no clear benefit. Recently, the FDA has approved a novel drug,
which combines an angiotensin receptor neprilysin inhibitor and ARB (valsartan) named
LCZ696 (entresto) for possible treatment of HFrEF.
Conclusion: In this article, we will discuss the failure of previous treatment modalities and the
promise that LCZ696 (entresto) may hold for treating patients with HFpEF.